Skip to main content
. 2005 Jun 7;388(Pt 3):967–972. doi: 10.1042/BJ20041066

Figure 2. Cleavage of the substrate Cbz-Gly-Gly-Arg-AMC.

Figure 2

Cleavage of the substrate Cbz-Gly-Gly-Arg-AMC (100 μM) by 1.25 μg of active cellular immunopurified TMPRSS2 (×), 0.5 ng of trypsin (▲), 1.25 μg of active TMPRSS2 in the presence of 10 μM Cbz-Lys(OPh)2 (■) or 1.25 μg of active TMPRSS2 in the presence of 200 μM PAR-2 antagonist (Phe-Ser-Leu-Leu-Arg-Tyr-NH2) (*).